Progress in respiratory virus vaccine development.
Progress in respiratory virus vaccine development.
复制标题
DOI：
10.1055/s-0031-1283289
复制
发表时间：
2011-08
影响因子：
3.2
通讯作者：
Schmidt AC
中科院分区：
文献类型：
--
作者：
Schmidt AC
呼吸道病毒感染在婴幼儿以及高危成人和老年人中造成严重的发病率和死亡率。虽然许多病毒病原体都能引起呼吸道疾病，但疫苗开发必须集中在有限数量的病原体上，例如那些通常会导致严重下呼吸道疾病(LRI)的病原体。虽然流感病毒疫苗已经有一段时间了(参见Clark和Lynch在本期中的综述)，但还没有针对其他重要医学病毒的疫苗，如呼吸道合胞病毒(RSV)、副流感病毒(PIV)和偏肺病毒(MPV)。这篇综述旨在提供针对RSV、PIV和MPV的研究疫苗的最新进展，这些疫苗已经在临床试验中进行评估或目前正在临床开发中。
Viral respiratory infections cause significant morbidity and mortality in infants and young children as well as in at-risk adults and the elderly. Although many viral pathogens are capable of causing respiratory disease, vaccine development has to focus on a limited number of pathogens, such as those that commonly cause serious lower respiratory illness (LRI). Whereas influenza virus vaccines have been available for some time (see the review by Clark and Lynch in this issue), vaccines against other medically important viruses such as respiratory syncytial virus (RSV), the parainfluenza viruses (PIVs), and metapneumovirus (MPVs) are not available. This review aims to provide a brief update on investigational vaccines against RSV, the PIVs, and MPV that have been evaluated in clinical trials or are currently in clinical development.